Alnylam Pharmaceuticals Q3 2024 Adj EPS $(0.50) Beats $(0.93) Estimate, Sales $500.92M Miss $533.10M Estimate
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals reported a Q3 2024 adjusted EPS of $(0.50), beating the estimate of $(0.93). However, their sales of $500.92M missed the expected $533.10M.
October 31, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alnylam Pharmaceuticals reported better-than-expected Q3 2024 EPS but missed sales estimates. This mixed result may lead to short-term stock volatility.
The better-than-expected EPS suggests cost management or other efficiencies, which is positive. However, missing sales estimates could indicate challenges in revenue generation. These mixed results may lead to short-term stock volatility as investors weigh the positives against the negatives.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100